DURECT to Announce Q1 2024 Financials and Business Update

CUPERTINO, Calif., May 7, 2024 -- DURECT Corporation (Nasdaq: DRRX), an advanced biopharmaceutical enterprise, is leading the innovation of epigenetic therapies aimed at revolutionizing the treatment of severe and life-threatening conditions such as acute organ injury and cancer. The company has announced that it will release its financial results for the first quarter on Monday, May 13, 2024. Simultaneously, a conference call and webcast will be held by the management team to discuss these financial outcomes and provide a corporate progress update. The event is scheduled to commence at 4:30 pm Eastern Time.

DURECT Corporation specializes in the development of epigenetic drugs that address abnormal DNA methylation, with the goal of revolutionizing the treatment of critical health conditions. The company's main drug candidate, Larsucosterol, inhibits DNA methyltransferases (DNMTs), enzymes linked to hypermethylation in patients suffering from alcohol-associated hepatitis (AH). Larsucosterol is currently in clinical trials for AH treatment and has received Fast Track Designation from the U.S. Food and Drug Administration (FDA). Additionally, DURECT offers POSIMIR® (bupivacaine solution) for infiltration use, a non-opioid pain reliever that uses the SABER® platform technology. POSIMIR is FDA-approved and licensed exclusively to Innocoll Pharmaceuticals for distribution within the United States.

The upcoming financial report will shed light on DURECT's economic health and strategic developments. In particular, the company remains focused on advancing Larsucosterol through clinical trials, aiming to demonstrate its effectiveness in reducing mortality and liver transplant needs in AH patients. Nevertheless, the forward-looking statements in this press release caution that actual results may differ significantly from expectations due to various risks and uncertainties. These include potential delays in clinical trials, the possibility of the FDA requiring additional studies before approving Larsucosterol, and challenges in the successful commercialization of POSIMIR by Innocoll.

Risks also encompass financial concerns such as the sufficiency of DURECT's cash resources, capital requirements, and the need for additional financing. The company's ability to maintain its Nasdaq listing and secure funding for ongoing operations are additional areas of concern. Investors and stakeholders are encouraged to review DURECT's recent filings with the Securities and Exchange Commission (SEC) for a comprehensive understanding of these risks.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!